<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Regeneron Pharmaceuticals Said Phase 3 Trials of Invetigational Allergy Drug Meets Primary, Secondary Endpoints</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Regeneron Pharmaceuticals Said Phase 3 Trials of Invetigational Allergy Drug Meets Primary, Secondary Endpoints</h1>
  <ul>
<li>Regeneron Pharmaceuticals Said Phase 3 Trials of Invetigational Allergy Drug Meets Primary, Secondary Endpoints Regeneron Pharmaceuticals (REGN) said phase 3 trials evaluating its investigational allergen-blockin Upgrade</li>
<li>A Silver or Gold subscription plan is required to access premium news articles.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/regeneron-pharmaceuticals-said-phase-3-120537894.html">Source</a> · 2025-09-08T12:05:37+00:00</p>
</body>
</html>